Summary: This lawsuit involves a dispute between Genentech, Inc., Hoffmann-La Roche, Inc., and Chugai Pharmaceutical Co., Ltd. (collectively referred to as "Plaintiffs") and Biogen MA Inc. and Bio-Thera Solutions, Ltd. (collectively referred to as "Defendants"). The lawsuit centers around a patent infringement claim related to the drug Actemra® (tocilizumab), which is used to treat rheumatoid arthritis and other inflammatory diseases. Genentech, the licensed manufacturer and seller of Actemra®, has filed a lawsuit against Biogen, which is seeking FDA approval for a proposed biosimilar called "BIIB800" that is similar to Actemra®. The Plaintiffs allege that the Defendants' actions infringe on their patent rights. The lawsuit was filed in the United States District Court for the District of Massachusetts. The Plaintiffs argue that the court has jurisdiction over the case based on the patent laws of the United States and the Declaratory Judgment Act. They also claim that the court has personal jurisdiction over the Defendants because Biogen is incorporated in Massachusetts and Bio-Thera has availed itself of the benefits and protections of Massachusetts' laws. The Plaintiffs seek relief for patent infringement under Title 35 of the United States Code, Title 42 of the United States Code, and the Declaratory Judgment Act. They argue that the court has subject matter jurisdiction based on federal law. The lawsuit is based on the fact that Actemra® contains tocilizumab, a genetically engineered antibody that inhibits the activity of the cytokine interleukin 6 (IL-6). The Plaintiffs claim that the Defendants' proposed biosimilar, BIIB800, infringes on their patent rights. The lawsuit is ongoing, and the Plaintiffs have demanded a jury trial. The specific patents mentioned in the lawsuit include U.S. Patent Nos. 7,332,289; 7,521,052; 8,398,980; and others. Genentech seeks injunctive relief, damages, and other monetary relief under relevant sections of the U.S. Patent Act.
United States of America v. Robert Hunter Biden
Summary: Hunter Biden is currently embroiled in a lawsuit, accused of purchasing a Colt Cobra revolver in October 2018 while allegedly using illegal substances. Despite denying drug use on the necessary paperwork, if found guilty, he could face a maximum of 25 years in prison along with substantial fines. Biden's defense team contends that the charges are politically driven, asserting that Biden's temporary possession of an unloaded firearm did not constitute a public safety risk. They intend to contest the charges, leveraging an agreement with the prosecution, recent federal court decisions, and potential Second Amendment defenses. This case could potentially ignite wider discussions about Second Amendment rights, especially as the Supreme Court is poised to deliberate on a related issue concerning gun ownership for individuals subject to domestic violence restraining orders. Opinions are divided among political and legislative figures, with some speculating that advocates of the Second Amendment might oppose the law that prohibits gun ownership for drug users.
Robert Hunter Biden v. United States Internal Revenue Service
Improved Summary: Hunter Biden has filed a lawsuit against IRS whistleblowers Gary Shapley and an unidentified associate, along with their legal counsel, alleging they infringed upon his privacy rights by revealing his confidential tax information in media interviews. Biden is demanding $1,000 for each unauthorized disclosure, an unspecified amount in punitive damages, and a court directive for the IRS to implement a data security protocol in line with the Privacy Act. Critics, however, view the lawsuit as a strategic move by Biden's legal team to divert attention from his own legal challenges and discourage potential whistleblowers. The defendants' attorneys have pledged to resist any attempts at silencing by Biden's legal team. This lawsuit is part of a wider legal approach by Biden, who is concurrently addressing recent firearm charges and another lawsuit involving a former official from the Trump administration.
Edelson Pc V. David Lira Et Al
Summary: Erika Jayne, a cast member of "The Real Housewives of Beverly Hills," is currently facing a lawsuit filed by her former costume designer, Christopher Psaila. Psaila alleges that Jayne, in collaboration with American Express and the Secret Service, conspired to falsely accuse him of credit card fraud. According to Psaila, Jayne deliberately initiated fraudulent refund requests and bribed a Secret Service agent, through her husband, to press baseless felony charges against him. However, the case against Psaila was dismissed in 2021. Jayne's attorney has vehemently denied these allegations, describing them as "calculated." The lawsuit seeks $18.2 million in damages. This legal action comes on the heels of Jayne's involvement in another case where her husband was accused of embezzling $2 million from the families of victims in the 2018 Lion Air crash. Jayne filed for divorce in November 2020, and her husband's assets have been frozen as part of a separate legal proceeding.
Zornberg V. Napco Security Technologies, Inc. Et Al
Summary: A class action lawsuit has been initiated by the Law Offices of Howard G. Smith, representing investors who acquired securities from Napco Security Technologies, Inc. within the period of November 7, 2022, to August 18, 2023. The lawsuit was instigated following Napco's disclosure of inaccurate financial statements from Q3 2022 to Q1 2023, attributed to errors in their cost of goods sold (COGS) and inventory calculations. The suit accuses Napco of disseminating false and misleading statements, exaggerating inventory figures, understating COGS, and overlooking deficiencies in their internal controls. These actions precipitated a substantial decline in Napco's share price, resulting in investor losses. The lawsuit argues that Napco's previous optimistic statements were unfounded and deceptive. Investors are urged to contact Howard G. Smith to explore their legal options.